INTRODUCTION
There is a growing body of evidence that nutritional status influences the morbidity and mortality of children undergoing treatment for cancer; consequently achieving optimal nutritional status is of major importance as part of standard treatment practice. [1] [2] [3] Recent outcome studies indicate that clinical nutrition practice should not only be limited to preventing under nutrition but also decreasing the incidence of obesity in children diagnosed with leukemia. 4, 5 However, these studies are limited to the nutritional status of children at diagnosis and it is unknown if nutritional status during treatment affects outcome despite the observation that nutritional status changes throughout treatment. 6 Nutrition intervention before diagnosis is not possible, therefore it is important to direct nutritional intervention to a practical time point during therapy such as before hematopoietic stem cell transplantation (HSCT).
It is well documented that disease status and treatment-related variables such as pre-transplant chemotherapy, type of conditioning, type of donor and post transplant complications such as graft vs host disease are risk factors for HSCT-related mortality. [7] [8] [9] These variables are an essential and often unavoidable part of the treatment process. Other factors, however, such as nutritional status, may also have a role in contributing to survival after pediatric HSCT and may be more amenable to pre-HSCT intervention. Simple measures of nutritional status such as body mass index (BMI) or percent ideal body weight (%IBW) have not commonly been studied in large randomised outcome studies of bone marrow transplantation in children. 8, 9 Previous studies have reported that children pre-HSCT are generally well nourished as a group according to anthropometric measures; however, there can be a large variation in nutritional status. 10, 11 The importance of optimal nutritional status pre-transplant is imperative as there is reduced opportunity to provide appropriate nutritional support during and post transplant owing to the intensity of conditioning regimes, mucositis and the possibility of graft vs host disease resulting in poor functional integrity of the gastrointestinal tract. 12 In view of the potential link between nutritional status and survival in pediatric HSCT patients and the lack of studies that have investigated this relationship, the aim of this study is to investigate the association between nutritional status pre-HSCT and survival in a pediatric population.
SUBJECTS AND METHODS

Patient characteristics
and donor type, the initial diagnosis of the patient and the type of conditioning used. The outcome measure was overall survival. Survival was defined as the time from the start of conditioning for the transplant until death. The study protocol was approved by the Royal Children's Hospital Ethics Committee.
Anthropometry
Patients were divided into three groups according to their calculated %IBW: underweight, ideal weight and overweight. Weight and height were obtained 9 days pre-transplant. IBW was determined by identifying the patient's height percentile and selecting the IBW on the corresponding weight percentile, the growth charts for children up to 18 years produced by Centers for Disease Control and Prevention where used. 13 The patient's %IBW was calculated by dividing their actual weight by their ideal weight, a method recommended by the Oncology Nutrition Dietetic Group, The American Dietetic Association. 14 Underweight, ideal weight and overweight cutoffs were taken from the Children's Oncology Group Nutrition Committee. 15 A patient was defined as underweight if their %IBW was o90; as ideal weight if their %IBW was between 90 and 110; and as overweight if their %IBW was 4110.
Transplantation procedure and definitions
Transplant procedures were classified by: (i) donor source (autologous/ related/unrelated); (ii) conditioning therapy (myeloablative/non-myeloablative); (iii) disease type (malignant/non-malignant). Donor source and conditioning therapy were associated with significantly different survival outcomes, as expected. For patients who underwent multiple transplants, transplant parameters at the first transplant were recorded.
Patients were hospitalized in single rooms ventilated with highefficiency particulate air filtration systems. Documented cytomegalovirus reactivation or infection shown by molecular PCR testing after transplantation was treated with therapeutic doses of either foscarnet or ganciclovir. Patients at risk for recurrence of herpes simplex received prophylactic intravenous acyclovir. Broad-spectrum empiric antibiotics and antifungal therapy were administered for fever based on institutional protocols. Patients received prophylaxis with co-trimoxazole for Pneumocystis carinii after engraftment. A range of preparative regimens were used over the study period. The commonest of these used total body irradiation, delivered up to a dose of 12 Gy over 3 days in six fractions by linear accelerator followed by cyclophosphamide 60 mg/kg per day for 2 days or Busulphan 16 mg/kg in total delivered orally every 6 h for 4 days followed by cyclophosphamide 50 mg/kg per day for 4 days.
Statistical methods
All patients included in the study were followed for at least 3 years post-BMT, or until death. Demographic and clinical characteristics are compared using either the Mann-Whitney test (continuous data) or Fisher's Exact Test (categorical data). Cox proportional hazards regression analysis was used to assess the difference in survival between different weight categories. Overweight and underweight patients were compared separately with ideal-weight patients. We first calculated unadjusted hazard ratios (HR) and 95% confidence intervals, and then calculated adjusted HR's after adjusting for age, sex, donor source, conditioning therapy and year of transplant. Significance was set at Pp0.05. Data analysis was undertaken by using Stata 11.0 for Windows (Stata Corp., College Station, TX, USA).
RESULTS
There were 113 eligible patients in the study period; 15 (12.6%) were underweight and 41 (34.5%) were overweight. Patients had a wide variety of malignant (n ¼ 97) and non-malignant (n ¼ 16) diagnoses (Table 1) . Patient and transplant characteristics are listed in Table 2 . The overweight and ideal-weight groups did not differ significantly. However, compared with the ideal-weight group, underweight patients were more likely to be older (P ¼ 0.0002), allogeneic (P ¼ 0.03), have myeloablative conditioning (P ¼ 0.04), and have additional chemotherapy added to total body irradiation/Cyclophosphamide (Fludarabine, Thiotepa, Melphalan or Etoposide ± lymphocyte immune globulin ATGAM, (ATG antithymocyte globulin)) (P ¼ 0.03). There was no difference in the proportion of patients that received total body irradiation across the %IBW categories.
The median follow-up from the date of transplantation was 6.9 years. The range of follow-up times for patients alive at study completion was 3.1-11.5 years. Figure 1 shows the survival rate of the %IBW categories. At 3 years post-HSCT 55 (49%) patients were alive; 6 (40%) in the underweight group, 34 (60%) in the idealweight group and 15 (37%) in the overweight group. The univariate HR for mortality was significantly increased in overweight patients compared with ideal-weight patients (HR; 95% confidence interval ¼ 1.97; 1.14-3.40) ( Table 3 ). This association 
DISCUSSION
This study showed that overweight children undergoing autologous and allogeneic HSCT are less likely to survive than patients who are ideal weight. Inferior survival of overweight patients has been observed previously in children with acute lymphoblastic leukemia and acute myeloid leukemia. 4, 5 This is concerning, particularly as 23% of patients receiving treatment for acute lymphoblastic leukemia have been identified as being obese (%BMI X95%) by the conclusion of treatment. 6 Three studies in adult HSCT have shown that obesity causes decreased survival as a result of increased treatment-related mortality and relapse. [16] [17] [18] One of these studies incorporated a subset of 67 pediatric patients and found no relationship between survival and weight. 16 Explanations of why overweight children have decreased survival post-HSCT are inconclusive as there is a lack of cohesive and comprehensive literature in this area. One theory is that altered drug deposition may occur in obese patients. Oral busulfan clearance was studied in adolescents and adults who received stem cell transplants and clearance was higher in obese patients; however, once dosing was adjusted based on IBW no difference was found. 19 In a study of adults receiving autologous transplants, despite chemotherapy dose adjustments for obese patients, a higher non-relapse-related mortality was still observed. 17 In practice it is recommended that adjusted body weight be used in calculating chemotherapy requirements for children 4120% of IBW.
14 In the present study, the exact number of patients who underwent chemotherapy dose adjustment is unknown. Half of the overweight group would be classified as obese (X120% of IBW), therefore only a small number of subjects could be explained by the theory of altered pharmacokinetics. The relationship between survival and weight could be explained by more complex metabolic processes than drug deposition. The components of the 'metabolic syndrome' such as growth factors, lymphokines and leptins may alter anticancer effects and effect survival. 20 It has been established that underweight children with leukemia and solid tumors have an increased rate of relapse and worse survival.
3,4,21 A significant difference in survival was not observed between the underweight and ideal-weight groups. Although not significant, an increased HR was observed with large confidence intervals, indicating that further investigation with larger numbers in the underweight group is required. The underweight group differed significantly from the ideal-weight group in age, transplant and conditioning type. Transplant and conditioning type were controlled for; however, the age was not. The underweight group was significantly older than the ideal weight and overweight groups. However, this study found that age had no significant effect on outcome where as Woolfrey et al. found that children who were older than 10 years had lower leukemia free survival rates and a higher incidence of both severe graft vs host disease and regimen-related complications after HSCT.
This study used %IBW as an indicator of nutritional status, %IBW is commonly used in the nutrition assessment of pediatric oncology patients. 2 Percent IBW has been found to be strongly and statistically significantly correlated with BMI during multiple pediatric oncology therapy time points making it an appropriate measure for weight categories. 15 Percent IBW is also able to be used for children o2 years of age therefore allowing the inclusion of the nine children in the study who were o2 years of age. Thirty-six percent of children in this study were found to be overweight (19%) or obese (17%) based on %IBW cutoffs recommended by the Children's Oncology Group Nutrition Committee, this is in excess of the normal population of Australian children where 23% have been found to be either overweight (17%) or obese (6%) as defined by BMI. 15, 22 Previous studies that have looked at nutritional status and survival have used BMI percentiles and cutoffs established by the Centers for Disease Control and Prevention National Center for Health Statistics growth curves. 13 This retrospective study has the limitations that accompany a single-center cohort, which has not been prospectively designed to evaluate nutritional status and survival. It did not look at the cause of death for example, relapse related or treatment-related mortality. Dickson et al. 17 found in adults that underweight BMT patients experienced higher treatment-related mortality. Owing to the small patient numbers in this study, particularly in the underweight group (n ¼ 15), it would be difficult to determine the relationship between the cause of death and nutritional status. This would be best examined in a prospective multicenter study, which would also address the issue of limited statistical power of a single center study, center specific effects and the heterogeneity of the patient group. The HSCT procedures in this study were This study defines overweight by anthropometric measures, not by body composition measures; however, a strong correlation has been found between percent body fat and %IBW in the pediatric oncology population. 23 Future studies are suggested to examine the effect of body composition on survival in cancer patients, as it may be a low level of body cell mass (BCM) in the overweight patients that is leading to the poor survival. Previous studies have shown that pediatric cancer patients may have high fat mass but low BCM. 24 It may be the low amount of BCM in both the underweight and overweight patients that is linked to survival.
This study found that children who are overweight or obese before HSCT are more likely to have decreased survival compared with ideal-weight children. The reasons behind this cannot be determined from this study; however, the clinical implications are that nutrition intervention should be a focus for both underweight and overweight children before bone marrow transplant. Previously, undernutrition has been the focus of nutritional support in pediatric oncology with the levels of malnutrition been reported to be as high as 50% in some diagnosis categories. 25 Management of obesity is usually not part of routine clinical nutrition management in pediatric oncology patients; however, this paper builds on the evidence that a change in clinical practice is required. Particularly as interventions are possible before HSCT, prevention of weight gain and weight loss strategies could be employed at this time point during treatment. Future studies should be focused on nutrition and exercise interventions before HSCT and the effect this has on improving survival.
